Drug Profile
IQ 004
Alternative Names: Interferon-alpha autoantibody - ImmunoQure; Interferon-alpha human autoantibody - ImmunoQure; Interferon-alpha neutralising autoantibody - ImmunoQure; IQ004Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator ImmunoQure AG
- Class Monoclonal antibodies
- Mechanism of Action Interferon alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in Germany
- 22 Feb 2023 Servier terminates development of neutralising interferon-alpha antibodies and return the rights to ImmunoQure
- 11 Sep 2019 Preclinical trials in Autoimmune disorders in Germany (unspecified route) before September 2019 ImmunoQure pipeline September 2019)